Luye Pharma Group (HK:2186) has released an update.
Luye Pharma Group announces its partner Towa Pharmaceutical Co., Ltd. has filed a New Drug Application in Japan for their Rivastigmine Twice Weekly Transdermal Patch, designed to treat dementia related to Alzheimer’s disease. Developed on Luye Pharma’s proprietary platform, the patch offers a less frequent administration, potentially improving medication adherence for patients. Already approved in multiple European countries and China, the patch is also being developed for markets in Southeast Asia and Latin America.
For further insights into HK:2186 stock, check out TipRanks’ Stock Analysis page.
